First trimester fetal nuchal translucency.
This review examines the development of a new method of screening for Down's syndrome based on the combination of fetal nuchal translucency thickness, maternal age and maternal serum biochemistry at 10-14 weeks of gestation. This method can potentially identify more than 80% of affected fetuses for a false-positive rate of less than 5%.
['Chorionic Gonadotropin/blood', 'Chorionic Gonadotropin, beta Subunit, Human', 'Chromosome Aberrations/diagnosis/*diagnostic imaging', 'Chromosome Disorders', 'Down Syndrome/diagnosis/diagnostic imaging', 'Female', 'Humans', 'Maternal Age', 'Neck/diagnostic imaging', 'Peptide Fragments/blood', 'Pregnancy', 'Pregnancy Trimester, First', 'Pregnancy-Associated Plasma Protein-A/analysis', 'Prenatal Diagnosis', 'Sensitivity and Specificity', '*Ultrasonography, Prenatal']